A cyclometallated ir(III)-azt compound, its preparation method and application

By preparing cyclic metallized Ir(III)-AZT compounds, photodynamic therapy was used to generate reactive oxygen species in the acidic environment of tumors, and combined with the enrichment of zidovudine in organelles, the problems of high dark toxicity and insufficient photodynamic effect of existing cyclic metal iridium complexes were solved, achieving low-toxicity and high-efficiency tumor cell killing and enhanced immunotherapy.

CN121517467BActive Publication Date: 2026-07-24HOSPITAL OF STOMATOLOGY SUN YAT SEN UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN Β· China
Patent Type
Patents(China)
Current Assignee / Owner
HOSPITAL OF STOMATOLOGY SUN YAT SEN UNIV
Filing Date
2025-11-24
Publication Date
2026-07-24

AI Technical Summary

Technical Problem

Existing cyclic iridium(III) complexes suffer from high dark toxicity and insufficient photodynamic efficacy in photodynamic therapy, making it difficult to meet the clinical treatment needs of oral squamous cell carcinoma.

Method used

A cyclometalated Ir(III)-AZT compound was developed, which generates reactive oxygen species under laser irradiation in the acidic environment of tumors, combines with the specific enrichment of zidovudine in organelles, induces immunogenic cell death, and is used in combination with immunosuppressants to enhance antitumor effects.

Benefits of technology

It achieves low dark toxicity and high phototoxicity index, effectively killing tumor cells and enhancing anti-tumor effects through immunotherapy, making it suitable for the treatment of oral squamous cell carcinoma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121517467B_ABST
    Figure CN121517467B_ABST
Patent Text Reader

Abstract

The application relates to the field of nanobiomedicine, in particular to a cyclometalated Ir(III)-AZT compound and a preparation method and application thereof. The application prepares a cyclometalated Ir(III)-AZT compound, which has low dark toxicity and excellent photodynamic anti-tumor activity. In a tumor acid environment, the iridium complex in the compound generates various ROS through type I / II photodynamic under light, the zidovudine in the compound mediates stress conduction from the endoplasmic reticulum to the mitochondria, both of which synergistically induce immunogenic cell death, and simultaneously promote the release of tumor antigens and damage-associated molecular patterns. In addition, the synergistic treatment can adaptively up-regulate the PD-L1 expression of tumor cells, and the combination with an immunosuppressive agent (such as PD-L1) can further synergistically inhibit tumor growth, relieve the immunosuppressive microenvironment in the body, and realize the dual anti-tumor effect of "photodynamic + immune synergy".
Need to check novelty before this filing date? Find Prior Art